Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
Recruiting
Observational Study
Checkpoint Inhibitor-related Pneumonitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Zhou Chengzhi · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of precise and effective diagnostic techniques often leads to underdiagnosis and misdiagnosis. The investigators conducted a prospective clinical study to evaluate the effectiv…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients with a pathological diagnosis of lung cancer;
2. The subject has received at least one course of immune checkpoint inhibitor treatment;
3. Capable of understanding and voluntarily signing an informed consent form.
For the CIP group, the following additional crite…
Contacts